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ABSTRACT 
In congestive heart failure (CHF), sympathetic nervous 
system is hyperactive. This article reviews current 
understandings about central and peripheral neural 
mechanisms underlying sympathetic hyperactivation 
in this pathological condition. During the development 
of CHF, renin-angiotensin system (RAS) activities 
and angiotensin II–mediated oxidative stress become 
enhanced. Here, on the basis of findings obtained from 
animal studies, it is examined how RAS overactivation 
and oxidative stress in central and peripheral nervous 
systems of CHF mediate sympathetic hyperactivation. 
Mechanisms by which exercise training in CHF amelio-
rates RAS overactivation, oxidative stress and sympa-
thetic hyperactivation are also investigated. 
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sympathetic nervous system 
Congestive heart failure (CHF) is a common and lethal 
syndrome earmarked by systemic perfusion insufficient 
to meet the peripheral organs’ metabolic demands as a 
result of attenuated cardiac pump function. This disease 
binds enormous medical resources and therefore is a 
major public health problem in developed countries 
including Japan. In Japan, as the incidence of CHF in-
creases with age, the disease pandemic is expected to be 
evident by 2030.1  
 In CHF, sympathetic nervous system becomes 
hyperactive at rest as well as during exercise. Elevated 
plasma norepinephrine levels seen in patients with 
CHF have been reported.2 The microneurographic 
experiments performed by Leimbach and colleagues 
provided direct evidence for increased discharges of 
muscle sympathetic postganglionic neurons in resting 
patients with CHF.3 The level of sympathoexcitation 
seen during voluntary exercise is also excessive in CHF 
patients compared to that in control subjects.4, 5 While 
sympathetic hyperactivation can initially be interpreted 
as short-term compensatory responses to hemodynamic 
alterations due to impaired cardiac function, chronic hy-
peractivaiton of sympathetic nervous system drives mal-
adaptive remodeling, and promotes further deterioration 
in cardiac function and disease progression.6 The level 
of sympathetic hyperactivation at rest is a possible index 
to predict the mortality of CHF patients.7 Exaggerated 
sympathoexcitatory responses to exercise are a cause 
of exercise intolerance, a primary symptom of this dis-
ease.8 Therapeutic interventions that inhibit sympathetic 
hyperactivation favorably alter the natural course of the 
disease. 
 Sympathetic hyperactivation in CHF involves 
dysfunction of regulatory neural mechanisms of sympa-
thetic nervous system. However, it has not been fully un-
derstood how function of neural mechanisms becomes 
abnormal in CHF. Nevertheless, evidence has suggested 
that increased angiotensin II (AngII) and AngII-induced 
superoxide overproduction in central and peripheral 
nervous systems play a role in enhancing sympathetic 
vasomotor tone in CHF. Renin-angiotensin system (RAS) 
activity and oxidative stress become increased during 
the development of CHF.9 There is an interaction be-
tween the RAS activity and oxidative stress. Griendling 
et al. firstly demonstrated that stimulation of AngII 
receptor type 1 (AT1R) activated NADPH oxidases and 
increased superoxide production.10 Moreover, superoxide 
can increase the sensitivity of neuronal cells that respond 
to excitatory input.11 Thus, increased AngII likely has 
an excitatory effect on neural cells through action of 
superoxide. In this article, mechanisms by which RAS 
overactivation and AngII-mediated oxidative stress in 
central and peripheral nervous systems of CHF lead to 
sympathetic hyperactivation at rest and during exercise 
are discussed on the basis of findings obtained from an-
imal studies. Moreover, mechanisms by which exercise 
training in CHF, currently acknowledged as an effective 
therapeutic treatment, ameliorates RAS overactivation, 
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oxidative stress, and sympathetic hyperactivation are 
also examined. 
Central nervous system dysfunction due to RAS 
overactivation and oxidative stress in CHF
In CHF, plasma AngII levels are elevated in CHF due to 
the reduced renal blood flow and sodium delivery to the 
distal tubule that leads to renin release. Renin cleaves 
angiotensinogen to form the inactive decapeptide angio-
tensin I. In turn, angiotensin converting enzyme (ACE) 
cleaves angiotensin I to form the active octapeptide 
AngII. Renin release is further exacerbated by sympa-
thetically mediated renal vasoconstriction. As discussed 
below, increased plasma AngII likely acts on central 
cardiovascular pathways that lack blood-brain barrier 
(BBB), thereby playing a role in causing sympathetic 
hyperactivation. 
 There are various hierarchical brain sites that are 
known to generate sympathetic vasomotor tone. One of 
the most major among them is the paraventricular nucle-
us of the hypothalamus (PVN). The PVN contains cells 
that monosynaptically target the spinal cell column, in 
which cell bodies of sympathetic preganglionic neurons 
are located, and cells that innervate the rostral ventrolat-
eral medulla (RVLM), another cardiovascular region.12 
In rats with CHF after myocardial infarction, neurons 
in the PVN were hyperactive compared with healthy 
controls, and intracarotid artery injection of AT1R 
antagonist losartan reduced PVN neuronal activities to a 
larger degree than that in controls.13 These observations 
suggest that plasma AngII causes PVN neural overac-
tivities, thereby mediating sympathetic hyperactivation. 
Nevertheless, the PVN is located inside the BBB. Thus, 
the effect of increased plasma AngII to elevate the 
PVN neuronal activity is likely explained by its action 
on neurons upstream to the PVN that regulate PVN 
neuronal excitabilities. Neurons in the BBB-lacking sub-
fornical organ (SFO) contain AT1R abundantly and send 
axonal projections to the PVN (SFO-PVN neurons).14 
Zimmerman et al. showed that hypertension caused by 
chronic and systemic infusion of AngII in mice was 
correlated with significant elevations of superoxide 
production in the SFO, and that adenoviral-mediated de-
livery of cytoplasmically targeted superoxide dismutase 
(SOD) selectively to the SFO prevented the hypertension 
and increased superoxide production.15 These observa-
tions lead to the hypothesis that in CHF, elevated plasma 
AngII stimulates AT1R located on SFO-PVN neurons 
and increases superoxide production, thereby enhancing 
SFO-PVN neuronal activities. In turn, sympathoex-
citatory PVN neurons receive enhanced excitatory 
inputs from SFO-PVN neurons, and sympathetic nerve 
activity (SNA) is elevated in CHF (Fig. 1). The finding 
by Lindley et al. verifies the role played by brain oxida-
tive stress in enhancing excitabilities of SFO and PVN 
neurons, thereby causing sympathetic hyperactivation in 
CHF.16 They demonstrated that intracerebroventricular 
administration of an adenoviral vector encoding SOD in 
CHF mice not only inhibited neural hyperactivation in 
the PVN and SFO with CHF but also decreased urinary 
norepinephrine levels. 
 Endogenous AngII production is also increased in 
the PVN of CHF. All components of the RAS such as 
renin and angiotensinogen are abundantly expressed 
within the brain.17 Expressions of ACE and AT1R are 
upregulated in the brain regions including the PVN of 
CHF rats.18 The upregulation of ACE in central nervous 
system of CHF may be due to, at least in part, the 
increase in plasma aldosterone,19 that is released from 
the zona glomerulosa of the adrenal grands in response 
to plasma AngII, and penetrates the BBB unlike AngII. 
Intracerebroventricular administration of a selective 
antagonist of aldosterone mineralocorticoid receptor in 
CHF rats reduced expression of ACE and AT1R as well 
as NADPH oxidases–induced superoxide production in 
the PVN.18 Moreover, neurotransmitters released from 
SFO-PVN neurons include glutamate and AngII.14, 20 
Since SFO-PVN angiotensinergic neurons are consid-
ered to be excessively excited in CHF as stated above, 
angiotensinergic neurotransmission is likely enhanced 
in the PVN of CHF. Finally, Zheng et al. reported that 
AngII microinjected into the rat PVN increased SNA 
and that losartan microinjected into the PVN decreased 
SNA to a larger degree in CHF rats than those in healthy 
controls.21 Taken together, the endogenous AngII upreg-
ulation in the PVN of CHF is likely part of sympathetic 
hyperactivation (Fig. 1). 
 The RVLM contains neurons directly projecting to 
the spinal intermediolateral cell column, in which cell 
bodies of sympathetic preganglionic neurons are located. 
The basal activity of the RVLM sympathetic premotor 
neurons is a major mechanism responsible for the gen-
eration of resting sympathetic vasomotor tone.22 In the 
RVLM, there is a high density of ACE and AT1R.23, 24 
In the RVLM of CHF, expressions of ACE, AT1R, and 
NADPH oxidases become upregulated.23, 25 Gao et al. 
showed that cerebroventricular infusion of simvastatin, 
which impairs RAS hyperactivity,26 decreased expressions 
of AT1R and NADPH oxidase proteins and ameliorated 
superoxide production in the RVLM of CHF rabbits.25 
Blunted oxidative stress in the RVLM was associated 
with the decreased basal SNA. Thus, endogenous AngII 
mechanisms and therefore the superoxide pathway in the 
RVLM likely underlie sympathetic hyperactivaiton in 
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CHF (Fig. 1). 
 Oxidative stress in the RVLM of CHF mediates 
not only resting sympathetic hyperactivity but also 
exaggerated sympathoexcitation in response to exer-
cise. Sympathoexcitatory responses to exercise are 
mediated by a feedforward neural mechanisms termed 
central command. Central command evokes parallel 
modifications of motor and autonomic functions during 
exercise, and excites the central cardiovascular pathways 
containing the RVLM.27 We previously reported that 
central command-elicited sympathoexcitation becomes 
exaggerated in CHF by demonstrating that renal sym-
pathoexcitation in response to electrical stimulation of 
the mesencephalic locomotor region (MLR), stimulation 
of which evokes fictive locomotion under paralysis, 
was larger in rats with CHF than that in controls.28 
Subsequently, we demonstrated that administration 
within the RVLM of Tempol, a SOD mimetic, reduced 
MLR stimulation-elicited sympathoexcitation in CHF, 
suggesting the role of superoxide overproduction in the 
RVLM in enhancing central command-elicited sympa-
thetic outflow in CHF.29   
 Of note, a recent report by Biancardi et al. suggested 
that circulating AngII plays a role in increasing BBB 
permeability, thereby facilitating its access to central 
cardiovascular regions.30 They found that, the BBB 
permeability was increased along with downregulated 
key BBB protein constituents in the PVN and RVLM 
of spontaneously hypertensive rats that have increased 
plasma AngII as do CHF animal models. The BBB 
disruption was prevented by oral administration of 
losartan. In CHF, it is hypothesized that plasma AngII 
can extravasate into central cardiovascular regions inside 
the BBB, thereby stimulating the AT1R in the PVN and/
or RVLM and mediating sympathetic hyperactivation as 
does endogenous AngII. Future studies are required to 
test this hypothesis. 
Baroreflex dysfunction due to overactivation of 
RAS and oxidative stress in CHF
We need to note the important roles of reflex mecha-
nisms that regulate central cardiovascular pathway ac-
tivities and therefore the level of sympathetic vasomotor 
tone. The arterial baroreflex is a homeostatic mechanism 
Fig. 1. A schema for the involvement of RAS overactivation and oxidative stress in central and peripheral neural mechanisms that under-
lie the level of sympathetic nerve activities in CHF based on works cited in text. AngII, angiotensin II; BBB, blood-brain barrier; CHF, 
congestive heart failure; EPR; exercise pressor reflex; PVN, paraventricular nucleus of the hypothalamus; RAS, renin-angiotensin system; 
RVLM, rostral ventrolateral medulla; SFO, subfornical organ. 
skeletal muscle
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by which the level of SNA changes through sensing the 
alteration of tension in arterial vascular walls. Arterial 
baroreceptors are located in the arterial blood vessels 
including aortic baroreceptor neurons in the nodose gan-
glion and carotid baroreceptor neurons in the petrosal 
ganglion. They sense the mechanical deformation of 
arterial vascular walls associated with arterial pressure 
changes, thereby exciting or inhibiting aortic barorecep-
tor neurons. In turn, neural signals are sent to central 
cardiovascular pathways through the nucleus tractus 
solitarii (NTS). When barosensitive afferents transmit 
excitatory signals to the NTS due to the elevation of 
arterial pressure, the NTS send excitatory signals to 
the caudal ventrolateral medulla, that sends inhibitory 
signals to the RVLM. Patients with CHF exhibit the 
attenuated baroreflex sensitivity, which contributes to 
sympathetic hyperactivation.31, 32   
 Intravenous infusion of AngII has the effect to 
downregulate the baroreflex control of SNA in healthy 
animals.33 DiBona et al. demonstrated that, in rats with 
CHF, intravenous administration of AT1R antagonist 
losartan partially restored the impaired baroreflex con-
trol of SNA,34 suggesting that increased plasma AngII in 
CHF mediates arterial baroreflex dysfunction (Fig. 1). 
 Enhanced AngII-NADPH oxidase-superoxide 
signaling in the periphery of CHF likely mediates dys-
function of aortic baroreceotor neurons. Via whole cell 
patch-clamp recordings, AngII enhanced the density 
of hyperpolarization-activated currents, and decreased 
membrane excitabilities in the aortic baroreceptor 
neurons.35 Moreover, either losartan or apocynin, a 
NADPH oxidase inhibitor, blunted the AngII-induced 
increases in the hyperpolarization-activated currents 
and decreases in the membrane excitability in the aortic 
baroreceptor neurons. In their subsequent study,36 AT1R 
expression and local AngII concentration in the nodose 
ganglia were upregulated in CHF. Moreover, local mi-
croinjection of losartan into the nodose ganglia of CHF 
significantly increased the sensitivity of arterial barore-
flex that was impaired. Furthermore, local application of 
AngII in the nodose ganglia from healthy rats mimicked 
CHF to depress the arterial baroreflex function. These 
results suggest that elevation of AngII associated with 
AT1R overexpression in the nodose ganglia contributes 
to the aortic baroreceptor dysfunction and subsequent 
downregulation of the arterial baroreflex sensitivity in 
CHF rats. This group also reported that adenoviral gene 
transfection of manganese SOD into the nodose neurons 
reduced the elevation of mitochondrial superoxide in 
CHF rats, and partially reversed the suppressed cell 
excitabilities.37 Mitochondria-derived superoxide over-
production in the aortic baroreceotor neurons of CHF 
also likely impairs arterial baroreflex control of SNA.  
Exercise pressor reflex dysfunction due to overac-
tivation of RAS and oxidative stress in CHF
Elevated AngII concentration in the periphery of CHF 
plays a role in exaggerating sympathoexcitation in re-
sponse to exercise by acting on neural arc of the exercise 
pressor reflex (EPR). The EPR originates in exercising 
skeletal muscle from chemical and mechanical acti-
vation of nerve endings of thin fiber muscle afferents 
(i.e., group III and IV). Signals from the nerve endings 
project to the dorsal horn of the spinal cord and then 
to the central cardiovascular pathways. In turn, muscle 
afferent engagement during exercise reflexly causes 
sympathoexcitatory and pressor responses.38 Smith et al. 
reported that the reflex pressor response to contraction 
of hindlimb skeletal muscle of CHF rats was larger 
than that of controls, suggesting the exaggerated EPR.39 
We previously found that exaggerated EPR in CHF is 
mediated by oxidative stress in skeletal muscle by show-
ing that Tempol infused into the hindlimb circulation 
significantly reduced sympathoexcitotory responses to 
hindlimb skeletal muscle contraction in CHF rats but 
not in healthy controls.40 Subsequently, we reported that 
subcutaneous administration of AngII for two weeks 
enhanced the reflex sympathoexcitaotry response to 
skeletal muscle contraction in rats, suggesting the role 
of increased plasma AngII in enhancing the EPR.41 The 
enhanced EPR response was reduced by pretreatment 
with Tempol of exercising skeletal muscle. Taken togeth-
er, AngII-mediated oxidative stress in skeletal muscle 
in CHF is considered an important factor to exaggerate 
sympathoexcitatory responses to exercise via the EPR 
arc (Fig. 1).  
Beneficial effects of exercise training in CHF to 
ameliorate RAS activation, oxidative stress, and 
sympathetic hyperactivation 
Exercise training interventions in patients with CHF 
have currently been an accepted adjunct to an evidence 
based management program. This therapy not only re-
duces symptoms and improves self-reported measures of 
quality of life without adverse events but also alleviates 
sympathetic hyperactivation.42  
 Alleviated sympathetic hyperactivity in CHF after 
exercise training is due to, at least in part, its effect to re-
duce plasma AngII. Liu et al. showed that exercise train-
ing lowered resting sympathetic hyperactivity and im-
proved arterial baroreflex dysfunction in conscious rab-
bits with CHF but not in healthy controls.43 Intravenous 
infusion of losartan enhanced baroreflex sensitivity 
in CHF rabbits that were not exercise trained but had 
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no effect in CHF rabbits that were exercise trained. 
Concomitant with this effect, exercise training lowered 
the elevated plasma AngII concentration in CHF rabbits, 
and there was a significant positive correlation between 
SNA and plasma AngII. These observations suggest that 
exercise training ameliorates baroreflex dysfunction and 
alleviates sympathetic hyperactivity by lowering plasma 
AngII. 
 Exercise training in CHF can also normalize angio-
tensinergic mechanisms in central nervous system. Kar 
et al. reported that overexpression of ACE in the PVN 
of CHF rabbits was decreased after exercise training.23 
Zheng et al. found that renal sympathoexcitation in 
response to microinjection of AngII into the PVN was 
larger in CHF rats than in healthy controls, and the 
enhanced sympathoexcitatory response was normalized 
after exercise training.44 Moreover, losartan microinject-
ed into the PVN reduced SNA in CHF rats had no effect 
in healthy controls and CHF animals after exercise 
training. Finally, overexpression of AT1R in the PVN of 
CHF was reduced after exercise training. Reduced RAS 
activity in the PVN of CHF after exercise training is 
likely part of alleviated sympathetic hyperactivity.  
 In the RVLM of CHF, exercise training reduced 
overexpressions of ACE and AT1R,23, 45 suggesting that 
RAS overactivation are suppressed. Mousa et al. report-
ed that, in CHF rabbits that were exercise trained, sub-
cutaneous infusion of AngII to experimentally maintain 
plasma AngII levels near levels of untrained rabbits with 
CHF prevented the effects of exercise training to amelio-
rate baroreflex dycfunction and sympathetic hyperactivi-
ty and cancelled exercise training-downregulated AT1R 
expression in the RVLM.45 These observations suggest 
that the beneficial effects of exercise training on resting 
sympathetic hyperactivity and baroreflex dysfunction 
in CHF are a result of, at least in part, concomitant 
reductions of RAS activities in the RVLM. Gao et al. 
reporeted that exercise training increased expression 
of Cu,Zn SOD and decreased expression of NADPH 
oxidase subunit gp91phox in the RVLM of CHF rabbits.46 
Thus, an upregulation in antioxidative mechanisms 
and suppressed prooxidant mechanisms in the RVLM 
contribute to beneficial effects of exercise training to 
ameliorate sympathetic hyperactivity in CHF. 
 In patients with CHF, exercise training interventions 
also ameliorate acutely elicited sympathoexcitatory re-
sponses to exercise that are exaggerated.47 This effect is 
likely a result of normalizations of central command and 
EPR dysfunction.29, 48 We previously demonstrated that 
the normalization of central command dysfunction in 
CHF after exercise training was due to its antioxidative 
effects in the RVLM.29 Tempol microinjected into the 
RVLM reduced central command-elicited sympatho-
excitation in rats with CHF but had no effect in CHF 
animals after exercise training. Moreover, since the 
EPR becomes exaggerated by AngII-mediated oxidative 
stress in skeletal muscle,41 ameliorated RAS overacti-
vation in skeletal muscle after exercise training49 likely 
underlies the normalization of the EPR dysfunction in 
CHF.   
Conclusion
This article focused on RAS overactivation and AngII-
mediated oxidative stress in central and peripheral 
nervous systems, which play an important role in caus-
ing sympathetic hyperactivation in CHF. Mechanisms 
underlying beneficial effects of exercise training on 
RAS overactivation, oxidative stress and sympathetic 
hyperactivity in CHF were also examined. However, 
questions have still remained unanswered. For example, 
mechanisms underlying upregulation of proteins related 
to RAS activity and oxidative stress in central and 
peripheral nervous systems of CHF have remained to 
be investigated. Mechanisms by which exercise training 
in CHF downregulates the protein expressions are also 
unknown. These issues need to be addressed in future 
studies. 
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